Hospital

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.

The approval gives patients 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.

Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.

Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during cold and influenza season.

This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.

Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.

Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.

VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.

A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.

The panel discusses when cystatin C–based eGFR equations can improve kidney function estimates for drug dosing in older adults and patients with obesity, and why clinical judgment and follow-up remain essential.

The panel explains how to weigh safety and efficacy near kidney function dosing thresholds and how pharmacists can work with informatics teams to build BSA-adjusted estimated glomerular filtration rate (eGFR) into the electronic health record (EHR).

In an interview with Pharmacy Times, Victoria P. Werth, MD, discusses the 52-week AMETHYST findings for investigational litifilimab, meaningful improvement in cutaneous lupus, and the persistent symptoms that warrant specialist reassessment.

In an interview with Pharmacy Times, Ali A. Habib, MD, explains investigational cemdisiran’s mechanism and every-12-week dosing schedule, highlighting pharmacist responsibilities related to vaccination, infection-risk counseling, and potential use in generalized myasthenia gravis.

A panel of pharmacists explain how to bridge estimated creatinine clearance and the race-free CKD-EPI eGFR in dosing decisions while the field moves toward contemporary kidney function equations.

Heart failure with preserved ejection fraction (HFpEF) is often missed in primary care, and pharmacists can close care gaps by optimizing GDMT, including the nonsteroidal MRA finerenone.

Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.

In an interview with Pharmacy Times, Ali A. Habib, MD, discusses hospitalization findings from the NIMBLE trial of investigational cemdisiran in generalized myasthenia gravis and explains why small event numbers require cautious interpretation.

Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.

Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.

In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.

As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.

In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence

The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.

Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.

In an interview with Pharmacy Times, Christine Brown, PhD, and John Williams, PhD, discuss how an investigational meditope-enabled CAR T-cell platform could offer control through adapter dosing and the pharmacist’s role in its clinical development.

The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.